At the same time that it closed its first significant financing round - a $36 million Series A - Lux Biosciences Inc. gained worldwide rights to a late-stage immunosuppressant drug from Isotechnika Inc. to develop for ophthalmic diseases. (BioWorld Today)

At the same time that it closed its first significant financing round - a $36 million Series A - Lux Biosciences Inc. gained worldwide rights to a late-stage immunosuppressant drug from Isotechnika Inc. to develop for ophthalmic diseases. (BioWorld Today)